Product Description
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Peripheral Neuroectodermal Tumors, Primitive|Leiomyosarcoma|Synovial Sarcoma|Sarcoma, Ewing|Head and Neck Cancer|Squamous Cell Carcinoma|Adenocarcinoma|Primitive Neuroectodermal Tumors|Prostate Cancer|Rhabdomyosarcoma|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Uveal Melanoma|Male Breast Cancer|Pancreatic Cancer|Gliosarcoma|Colorectal Cancer|Liver Cancer|Osteosarcoma|Soft Tissue Cancer|Esophageal Cancer|Hemangiosarcoma|Peritoneal Cancer|Neurofibrosarcoma|Liposarcoma|Alveolar Rhabdomyosarcoma|Alveolar Soft Part Sarcoma|Embryonal Rhabdomyosarcoma|Large Cell Carcinoma|Neuroendocrine Carcinoma|Adrenocortical Carcinoma|Kidney Cancer|Wilms Tumor|Embryonal Carcinoma|Neuroblastoma|Hepatoblastoma|Breast Cancer|Mesothelioma|Neuroendocrine Tumors|Retinoblastoma|Bronchiolo-Alveolar Adenocarcinoma|Gastrointestinal Cancer|Small Cell Lung Cancer
Phase 1: Thrombocytopenia|Oncology Solid Tumor Unspecified|Hyperglycemia|Insulinoma|Islet Cell Carcinoma|Glucagonoma|Neuroendocrine Tumors|Anemia|Hypertension|Paraganglioma|Pancreatic Cancer|Somatostatinoma|Carotid Body Tumor|Medullary Carcinoma|Carcinoma, Merkel Cell|Carcinoid Tumor|Neuroendocrine Carcinoma|Neutropenia|Malignant Carcinoid Syndrome|Gastrinoma|Gastrointestinal Cancer|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Peripheral Neuroectodermal Tumors, Primitive|Pinealoma|Hepatocellular Carcinoma|Glioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2011-03039 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2018-08-15 |
|
| NCI-2011-01917 | P2 |
Completed |
Small Cell Lung Cancer |
2016-11-15 |
|
| 10-C-0146 | P2 |
Completed |
Mesothelioma|Peritoneal Cancer |
2016-08-13 |
|
| A Study in Non-Small Cell Lung Cancer | P2 |
Completed |
Squamous Cell Carcinoma |
2016-06-10 |